{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["31"],"submitter":["Shin J"],"funding":["A. Menarini Korea Ltd."],"pubmed_abstract":["<h4>Background</h4>This subanalysis of BENEFIT-KOREA cohort assessed the impact of baseline pulse rate (PR) and posttreatment PR reduction on the blood pressure (BP)-lowering efficacy of nebivolol in patients with hypertension.<h4>Methods</h4>South Korean patients with hypertension were enrolled in the BENEFIT-KOREA study; 3,011 patients received nebivolol as monotherapy/add-on therapy. Time-averaged BP, calculated by sum of the product of BPs at weeks 12 and 24 corrected for number of participants at these timepoints, was evaluated with/without adjustment for baseline BP. Change in BP in baseline PR groups of < 70, 70-79, and ≥ 80 beats/min and posttreatment PR reduction groups of < 1, 1-9, and ≥ 10 beats/min at 24 weeks were evaluated.<h4>Results</h4>The unadjusted time-averaged systolic"],"journal":["Clinical hypertension"],"pagination":["e8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11903211"],"repository":["biostudies-literature"],"pubmed_title":["Posttreatment pulse rate reduction and not baseline pulse rate as an indicator of blood pressure response to nebivolol: a subanalysis from the real-world BENEFIT-KOREA study."],"pmcid":["PMC11903211"],"pubmed_authors":["Cha DH","Kim SH","Hong SP","Do JY","Hwang WM","Lee M","Mancia G","Shin J","Manolis AJ","Jung IH","Koh YY","Bae WH"],"additional_accession":[]},"is_claimable":false,"name":"Posttreatment pulse rate reduction and not baseline pulse rate as an indicator of blood pressure response to nebivolol: a subanalysis from the real-world BENEFIT-KOREA study.","description":"<h4>Background</h4>This subanalysis of BENEFIT-KOREA cohort assessed the impact of baseline pulse rate (PR) and posttreatment PR reduction on the blood pressure (BP)-lowering efficacy of nebivolol in patients with hypertension.<h4>Methods</h4>South Korean patients with hypertension were enrolled in the BENEFIT-KOREA study; 3,011 patients received nebivolol as monotherapy/add-on therapy. Time-averaged BP, calculated by sum of the product of BPs at weeks 12 and 24 corrected for number of participants at these timepoints, was evaluated with/without adjustment for baseline BP. Change in BP in baseline PR groups of < 70, 70-79, and ≥ 80 beats/min and posttreatment PR reduction groups of < 1, 1-9, and ≥ 10 beats/min at 24 weeks were evaluated.<h4>Results</h4>The unadjusted time-averaged systolic","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-04-18T03:20:57.142Z","creation":"2025-04-03T23:56:41.576Z"},"accession":"S-EPMC11903211","cross_references":{"pubmed":["40083595"],"doi":["10.5646/ch.2025.31.e8"]}}